@article{0d76ad1b239c4f47ab9801485663cabf,
title = "A comparison of safety, tolerability and immunogenicity of Oka/Merck varicella vaccine and VARILRIX{\texttrademark} in healthy children",
abstract = "This study compared safety, tolerability, and immunogenicity of the Oka/Merck varicella vaccine and VARILRIX{\texttrademark} [Oka-RIT strain SmithKline Beecham Biologicals] in healthy children 12-24 months of age. Subjects were randomized in this double blind study to receive either a single dose of Oka/Merck varicella vaccine, (∼50,000 plaque forming units (PFU), Group A or ∼16,000PFU, Group B) or 1 dose of VARILRIX{\texttrademark}, (∼40,000PFU/dose, Group C). Safety profiles in each treatment group were similar. The proportions of subjects achieving a 6-week postvaccination titer ≥5 gpELISA units in Groups A, B or C were 97.1, 95.2 and 85.6%, respectively.",
keywords = "Immunogenicity, Varicella vaccination, Varicella zoster virus",
author = "Lau, {Yu Lung} and Vessey, {S. J.Rupert} and Chan, {Ivan S.F.} and Lee, {Tsz Leung} and Huang, {Li Min} and Lee, {Chin Yun} and Tzou-Yien Lin and Lee, {Bee Wah} and Kow Kwan and Kasim, {Siti M.} and Chan, {Christina Y.} and Kaplan, {Karen M.} and Distefano, {Daniel J.} and Harmon, {Anna L.} and Amy Golie and Jonathan Hartzel and Jin Xu and Shu Li and Holly Matthews and Sadoff, {Jerald C.} and Alan Shaw",
note = "Funding Information: This study was supported by a grant from Merck & Co. Inc.",
year = "2002",
month = jul,
day = "26",
doi = "10.1016/S0264-410X(02)00245-1",
language = "English",
volume = "20",
pages = "2942--2949",
journal = "Vaccine",
issn = "0264-410X",
publisher = "Elsevier BV",
number = "23-24",
}
